0

Drug Repurposing of Quinine as Antiviral Against Dengue Virus Infection

Shilu Malakar, Liji Sreelatha, Thanyaporn Dechtawewat, Sansanee Noisakran, Pa-Thai Yenchitsomanus, Justin Jang Hann Chu, Thawornchai Limjindaporn

Virus Res. 2018 Aug 15;255:171-178.

PMID: 30055216

Abstract:

Dengue virus (DENV) disease outbreaks continue to develop across the globe with significant associated mortality and economic burden, yet no treatment has been approved to combat this virus. In an attempt to identify novel drug candidates as therapeutics for DENV infection, we evaluated four US Food and Drug Administration (FDA) approved drugs including aminolevullic acid, azelaic acid, mitoxantrone hydrochloride, and quinine sulfate, and tested their ability to inhibit DENV replication using focus-forming unit assay to quantify virus production. Of the four investigated compounds, quinine was found to have the most pronounced anti-DENV activity. Quinine inhibited DENV production of DENV by about 80% compared to untreated controls, while the other three drugs decreased virus production by only about 50%. Moreover, quinine inhibited DENV production of all four serotypes of DENV. Reduction in virus production was documented in three different cell lines of human origin. Quinine significantly inhibited DENV replication by reducing DENV RNA and viral protein synthesis in a dose-dependent manner. In addition, quinine ameliorated expression of genes related to innate immune response. These findings suggest the efficacy of quinine for stimulating antiviral genes to reduce DENV replication. The antiviral activity of quinine observed in this study may have applicability in the development of new drug therapies against DENV.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP207671441 Quinine sulfate Quinine sulfate 207671-44-1 Price
qrcode